Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risperidone + olanzapine
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Risperidone and olanzapine are second-generation (atypical) antipsychotics used primarily for the treatment of schizophrenia and bipolar disorder. In the context of clinical research for treatment-resistant schizophrenia (TRS), such as the Lu AF35700 'DayBreak' trial, they are frequently utilized as the 'conventional therapy' or active comparator. Risperidone is a benzisoxazole derivative that acts as a potent D2 and 5-HT2A receptor antagonist. Olanzapine is a thienobenzodiazepine with a broader pharmacological profile, antagonizing D2, 5-HT2A, H1, M1, and alpha-1 receptors. Both agents are designed to provide antipsychotic efficacy with a lower incidence of extrapyramidal symptoms compared to first-generation antipsychotics.
- Other names
- risperidone and olanzapine
02
Targets
ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)HTR6 (5-hydroxytryptamine receptor 6)
Beyond the preview
Go deeper on risperidone + olanzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risperidone + olanzapine.